Botha Roelof, an insider at Natera Inc (NTRA), sold 1,225,298 shares on November 23, 2025, at a price of $231.23 per share, totaling $283.33 million. Following this transaction, Roelof retains 1,225,298 shares of the company.
Natera, headquartered in Austin, Texas, specializes in genetic testing services and employs 4,424 full-time staff. The company went public on July 2, 2015, and has a market capitalization of $32.7 billion. Natera's offerings include non-invasive prenatal testing (Panorama), tumor-specific assays (Signatera), and tests for transplant rejection (Prospera). The firm aims to enhance early detection of genetic conditions and monitor molecular residual disease in oncology.
Natera's upcoming earnings reports are scheduled for May 6, 2026, with an estimated EPS of -$0.50 and revenue of $613.6 million, followed by another report on August 5, 2026, with an estimated EPS of -$0.54 and revenue of $637.8 million.
Insider transactions provide transparency into executives’ perspectives on company stock, although they should not solely dictate investment decisions. Investors are encouraged to consider broader patterns of insider activity across multiple time periods and individuals.